Forecast

There is no analyst data available for this company.

News Go to news feed

Vivoryon cuts H1 2026 loss sharply and conducts advanced licensing talks

Vivoryon reports a net loss of €3.4m for H1 2026 versus €5.5m a year earlier, driven by a reduction in R&D and administrative expenses of 39.3% each. The biotech had €2.4m in cash at the end of June and expects a runway into Q4 2026 without using the standby share purchase agreement. Management reports advanced term-sheet negotiations for a licensing agreement for Varoglutamstat and talks with an investor specialized in kidney diseases. » More on de.investing.com
Vivoryon Therapeutics halves net loss thanks to cost cuts and promising candidate Varoglutamstat

Vivoryon Therapeutics reduced its net loss in 2025 by 56.8% to €8.9m and cut R&D and administrative expenses significantly. Clinical data on Varoglutamstat in kidney diseases were described as promising. Cash and cash equivalents amounted to €5.6m as of 31 Dec 2025 (pro-forma €10.7m) and are expected to fund operations until Q4 2026, subject to strategic partnerships and additional financing. Management regards partnerships as critical for continuing development and warns of competitive and trial-related risks. » More on de.investing.com